软组织肉瘤的分子靶点和新的治疗途径。
Molecular targets and novel therapeutic avenues in soft-tissue sarcoma.
机构信息
Cedars Cancer Centre, Department of Oncology, McGill University Health Centre, Montreal, QC.
Segal Cancer Centre, Department of Oncology, Sir Mortimer B. Davis Jewish General Hospital, Montreal, QC.
出版信息
Curr Oncol. 2020 Feb;27(Suppl 1):34-40. doi: 10.3747/co.27.5631. Epub 2020 Feb 1.
Abstract
Soft-tissue sarcoma (sts) represents a heterogeneous group of rare tumours, and a significant number of affected patients will develop metastatic disease. Outcomes in the population with metastatic disease are generally poor, especially after progression on standard chemotherapy. The advent of personalized medicine has permitted oncologists to offer targeted treatment, thus addressing the limited treatment options and poor prognosis after progression on first-line chemotherapy. In this review, we delineate the existing data and therapeutic successes with respect to existing and emerging molecular targets in sts and options for immunotherapy in sts. Our review also summarizes emerging clinical trials that are currently recruiting patients.
摘要
软组织肉瘤（STS）是一组异质性罕见肿瘤，相当数量的患者会发展为转移性疾病。转移性疾病患者的预后一般较差，尤其是在标准化疗进展后。个性化医学的出现使肿瘤学家能够提供靶向治疗，从而解决了一线化疗进展后治疗选择有限和预后不良的问题。在这篇综述中，我们描述了 STS 中现有和新兴分子靶点的现有数据和治疗成功，并概述了 STS 中免疫治疗的选择。我们的综述还总结了目前正在招募患者的新兴临床试验。
相似文献
1
Molecular targets and novel therapeutic avenues in soft-tissue sarcoma.软组织肉瘤的分子靶点和新的治疗途径。
Curr Oncol. 2020 Feb;27(Suppl 1):34-40. doi: 10.3747/co.27.5631. Epub 2020 Feb 1.
2
Current state-of-the-art systemic therapy for pediatric soft tissue sarcomas.小儿软组织肉瘤的最新系统治疗方法。
Curr Oncol Rep. 2012 Aug;14(4):311-9. doi: 10.1007/s11912-012-0243-y.
3
Metastatic soft tissue sarcoma chemotherapy: an opportunity for personalized medicine.转移性软组织肉瘤化疗：个性化医学的机会。
Cancer Control. 2011 Jul;18(3):188-95. doi: 10.1177/107327481101800306.
4
Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma.晚期成人型软组织肉瘤的潜在联合化疗方法。
Am J Clin Dermatol. 2008;9(4):207-17. doi: 10.2165/00128071-200809040-00001.
5
Systemic therapy in pediatric-type soft-tissue sarcoma.小儿型软组织肉瘤的系统治疗。
Curr Oncol. 2020 Feb;27(Suppl 1):6-16. doi: 10.3747/co.27.5481. Epub 2020 Feb 1.
6
Update on systemic therapy for advanced soft-tissue sarcoma.晚期软组织肉瘤系统治疗进展。
Curr Oncol. 2020 Feb;27(Suppl 1):25-33. doi: 10.3747/co.27.5475. Epub 2020 Feb 1.
7
Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma.软组织肉瘤免疫检查点阻断的原理和新兴策略。
Cancer. 2018 Oct 1;124(19):3819-3829. doi: 10.1002/cncr.31517. Epub 2018 May 3.
8
Molecular landscape and therapeutic alterations in Asian soft-tissue sarcoma patients.亚洲软组织肉瘤患者的分子图谱和治疗改变。
Cancer Med. 2022 Nov;11(21):4070-4078. doi: 10.1002/cam4.4725. Epub 2022 May 18.
9
Novel treatment strategies for soft tissue sarcoma.软组织肉瘤的新型治疗策略。
Crit Rev Oncol Hematol. 2007 Apr;62(1):9-15. doi: 10.1016/j.critrevonc.2006.11.008. Epub 2006 Dec 1.
10
Immunotherapy in soft-tissue sarcoma.软组织肉瘤的免疫治疗。
Curr Oncol. 2020 Feb;27(Suppl 1):17-23. doi: 10.3747/co.27.5407. Epub 2020 Feb 1.
引用本文的文献
1
Study on the Effect of Antibiotics on the Efficacy of PD-1 Inhibitors and Its Regulatory Mechanism via the Intestinal Bacterial Community.抗生素对PD-1抑制剂疗效的影响及其通过肠道菌群的调控机制研究
Biochem Genet. 2025 Jul 12. doi: 10.1007/s10528-025-11189-x.
2
Exploring CX3CR1 as a prognostic biomarker and immunotherapeutic target in sarcoma.探索CX3CR1作为肉瘤的预后生物标志物和免疫治疗靶点。
Transl Oncol. 2025 Mar;53:102283. doi: 10.1016/j.tranon.2025.102283. Epub 2025 Jan 20.
3
The Next Frontier in Sarcoma: Molecular Pathways and Associated Targeted Therapies.肉瘤的下一个前沿领域：分子途径及相关靶向治疗
Cancers (Basel). 2023 Mar 9;15(6):1692. doi: 10.3390/cancers15061692.
4
Prospects for Epigenetic Targeted Therapies of Bone and Soft-Tissue Sarcomas.骨肉瘤和软组织肉瘤的表观遗传靶向治疗前景
Sarcoma. 2021 Jul 26;2021:5575444. doi: 10.1155/2021/5575444. eCollection 2021.
5
The Sarcoma Immune Landscape: Emerging Challenges, Prognostic Significance and Prospective Impact for Immunotherapy Approaches.肉瘤的免疫格局：免疫治疗方法面临的新挑战、预后意义及潜在影响
Cancers (Basel). 2021 Jan 20;13(3):363. doi: 10.3390/cancers13030363.
6
Efficacy and Safety of Apatinib Treatment for Patients with Advanced Intrahepatic Cholangiocarcinoma.阿帕替尼治疗晚期肝内胆管癌患者的疗效与安全性
Cancer Manag Res. 2020 Nov 10;12:11523-11526. doi: 10.2147/CMAR.S257526. eCollection 2020.
本文引用的文献
1
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.培昔替尼对比安慰剂治疗晚期腱鞘巨细胞瘤（ENLIVEN）：一项随机 3 期临床试验。
Lancet. 2019 Aug 10;394(10197):478-487. doi: 10.1016/S0140-6736(19)30764-0. Epub 2019 Jun 19.
2
Treatment of Desmoid Tumors in 2019.2019年硬纤维瘤的治疗
JAMA Oncol. 2019 Apr 1;5(4):567-568. doi: 10.1001/jamaoncol.2018.6449.
3
Sorafenib for Advanced and Refractory Desmoid Tumors.索拉非尼治疗晚期和难治性硬纤维瘤。
N Engl J Med. 2018 Dec 20;379(25):2417-2428. doi: 10.1056/NEJMoa1805052.
4
Tenosynovial giant cell tumor: case report of a patient effectively treated with pexidartinib (PLX3397) and review of the literature.腱鞘巨细胞瘤：一例使用培西达替尼（PLX3397）有效治疗的患者病例报告及文献综述
Clin Sarcoma Res. 2018 Jul 10;8:14. doi: 10.1186/s13569-018-0101-2. eCollection 2018.
5
Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 T Cells in Synovial Sarcoma.过继转移 NY-ESO-1 细胞在滑膜肉瘤中与抗肿瘤活性相关联，且具有持久的存在。
Cancer Discov. 2018 Aug;8(8):944-957. doi: 10.1158/2159-8290.CD-17-1417. Epub 2018 Jun 11.
6
Landscape of Microsatellite Instability Across 39 Cancer Types.39种癌症类型的微卫星不稳定性全景
JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00073. Epub 2017 Oct 3.
7
Targetable Alterations in Adult Patients With Soft-Tissue Sarcomas: Insights for Personalized Therapy.软组织肉瘤成人患者的靶向改变：个性化治疗的见解。
JAMA Oncol. 2018 Oct 1;4(10):1398-1404. doi: 10.1001/jamaoncol.2018.0723.
8
Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response.侵袭性纤维瘤病对他莫昔芬的反应：MRI与症状反应之间缺乏相关性。
Clin Sarcoma Res. 2018 May 14;8:13. doi: 10.1186/s13569-018-0100-3. eCollection 2018.
9
Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations.高分化/去分化脂肪肉瘤的靶向二代测序揭示了新的基因扩增和突变。
Oncotarget. 2018 Apr 13;9(28):19891-19899. doi: 10.18632/oncotarget.24924.
10
Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial.尼洛替尼治疗局部进展性色素绒毛结节性滑膜炎：一项多中心、开放标签、单臂、2 期临床试验。
Lancet Oncol. 2018 May;19(5):639-648. doi: 10.1016/S1470-2045(18)30143-8. Epub 2018 Mar 20.
Zotero 插件